UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the “Share Consolidation”). As a result of the Share Consolidation, each 40 ...

Core Points - Universe Pharmaceuticals INC has received a notice from Nasdaq regarding its delinquency in filing the Annual Report on Form 20-F for the fiscal year ended September 30, 2024, which could lead to delisting from Nasdaq [1] - The company is currently before a Hearings Panel for non-compliance with Listing Rule 5550(a)(2) and intends to request a stay of the suspension of its securities before February 26, 2025 [2] - The announcement is made in compliance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications [3] Company Overview - Universe Pharmaceuticals INC is headquartered in Ji'an, Jiangxi, China, and specializes in the production and distribution of traditional Chinese medicine derivatives aimed at improving the health of the elderly [4] - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products sold across 30 provinces in China [4]

Ji’an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has clo ...

Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 18,750,000 of the Company’s ordinary share, par value $0.28125 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share in a registered direc ...

Exhibit 99.1 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------|---------------------------| | ASSETS | March 31, 2024 \n(Unaudited) | As | of \nSeptember 30, 2023 | ...

Core Viewpoint - Universe Pharmaceuticals INC reported a significant decline in revenue and increased net loss for the first six months of fiscal year 2024, primarily due to decreased customer demand amid a global economic slowdown. The company is adapting its business strategy by developing online sales channels to drive future growth [2][3][4]. Financial Performance - Total revenues decreased by 30.2% to $12.9 million for the six months ended March 31, 2024, down from $18.5 million in the same period of 2023 [3][5]. - Loss from operations was $1.7 million for the six months ended March 31, 2024, compared to an income from operations of $0.1 million for the same period in 2023 [3][4]. - Net loss increased to $13.1 million for the six months ended March 31, 2024, from a net loss of $0.7 million in the prior year [3][17]. - Loss per share was $3.59 for the six months ended March 31, 2024, compared to a loss per share of $0.20 for the same period in 2023 [3][17]. Revenue Breakdown - Sales of traditional Chinese medicine derivatives (TCMD) products decreased by 26.7% to $6.87 million, with a sales volume decline of 23.4% [7][8]. - Sales of third-party products fell by 33.9% to $6.01 million, with a sales volume decrease of 29.9% [8][9]. Cost and Profitability - Cost of revenues decreased by 22.9% to $9.52 million, attributed to lower sales volume, despite a 10.8% increase in average cost of TCMD products [9][10]. - Gross profit decreased by $2.76 million to $3.37 million, with a gross margin decline to 26.2% from 33.2% [10][11]. Operating Expenses - Selling expenses increased by 74.0% to $4.05 million, primarily due to higher advertising costs [11]. - General and administrative expenses decreased by 29.8% to $0.97 million, mainly due to reduced bad debt expenses [12]. - Research and development expenses plummeted by 96.2% to $86,503, reflecting the completion of prior development activities [13]. Other Income and Losses - Total other expenses netted $10.70 million for the six months ended March 31, 2024, compared to total other income of $0.11 million in the previous year [14][15]. - The company recorded a realized loss on short-term investments of $3.09 million, contrasting with a gain of $0.17 million in the prior year [14]. Cash Flow and Balance Sheet - Net cash used in operating activities was $2.43 million for the six months ended March 31, 2024, compared to cash provided of $4.80 million in the same period of 2023 [19]. - As of March 31, 2024, the company had cash of $8.86 million, an increase from $5.29 million as of September 30, 2023 [18][19]. Subsequent Events - On July 15, 2024, the company closed a public offering of 20 million ordinary shares, raising $25 million before expenses [20].

Group 1 - Universe Pharmaceuticals (UPC) stock experienced a significant rally, closing up 43.9% on Friday, with over 716,000 shares traded, far exceeding its average daily volume of approximately 95,000 shares [1] - The stock is currently down 28.5% as of Tuesday morning, trading at about $1.81 per share, compared to $1.72 per share before the rally [2] - Year-to-date, UPC stock was up 30.9% when markets closed on Friday [2] Group 2 - The volatility in Chinese stocks may have influenced UPC's stock movement, and there are indications that some traders may be engaging in pump and dump strategies [1] - The company's float is approximately 1.55 million shares, which may contribute to the stock's volatility [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------|---------|----------------------| | | ASSETS | ASSETS CURRENT | March 31, 2023 | As of | September 30, 2022 | | | | Cash | $ 12,954 ...